Metabolic Flexibility, Gut Microbiota, Healthy Diet and Exercise in NAFLD on Genetics Base
Primary Purpose
Non-alcoholic Fatty Liver Disease, Obesity
Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Mediterranean diet
Low fat diet
Aerobic exercise
Sponsored by
About this trial
This is an interventional basic science trial for Non-alcoholic Fatty Liver Disease
Eligibility Criteria
Inclusion Criteria:
- body mass index (BMI) > 30 Kg/m2 and < 40 Kg/m2;
- Caucasian Italian subjects
- hepatic steatosis according with ultrasonographic Hamaguchi's criteria and/or hypertransaminasemia (ALT >30 IU/L in men and >20 IU/L in women)
Exclusion Criteria:
- any malignant disease during the last 5 years;
- any inflammatory or autoimmune disease;
- corticosteroids for systemic use;
- renal failure (GFR<90 ml/min);
- heart failure (NYHA classes II-IV);
- history of viral or autoimmune liver disease;
- any cause cirrhosis;
- excessive alcohol intake (>140g/week for men and 70g/week for women);
- participation in a reducing-weight program in the last 3 months;
- level of physical activity higher than 3 METs;
- therapy with antibiotics during the last 3 months;
- bile salts, cholestyramine during the last 6 months before enrollment;
- previous cholecystectomy;
- gallbladder disease
Sites / Locations
- Department of Translational and Precision Medicine, Sapienza University of Rome, Umberto I Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Mediterranean diet
Low fat diet
Arm Description
Hypocaloric Mediterranean diet for a 4-month period; Aerobic exercise training for a 4-month period;
Hypocaloric low fat diet supplemented by branched and essential amino acids considering the total protein intake for a 4- month period; Aerobic exercise training for a 4- month period;
Outcomes
Primary Outcome Measures
Cholesterol assessment
total cholesterol, HDL- cholesterol, LDL- cholesterol levels reported as mg/dl
Cholesterol assessment
total cholesterol, HDL- cholesterol, LDL- cholesterol levels reported as mg/dl
triglycerides assessment
tryglicerides levels reported as mg/dl
triglycerides assessment
tryglicerides levels reported as mg/dl
metabolic flexibility variation in liver function;
alanine aminotransferase (ALT) [U/L] , aspartate aminotransferase (AST) [UI/L]
metabolic flexibility variation in liver function;
alanine aminotransferase (ALT) [U/L] , aspartate aminotransferase (AST) [UI/L]
Waist circumference measurements;
waist circumference reported as cm
Waist circumference measurements;
waist circumference reported as cm
anthropometric measurements;
Body mass index reported as kg/m^2
anthropometric measurements;
Body mass index reported as kg/m^2
Ultrasonographic examination;
Liver ultrasonography according with criteria by Hamaguchi
Ultrasonographic examination;
Liver ultrasonography according with criteria by Hamaguchi
Glucidic profile
fasting glucose reported as mg/dl
Glucidic profile
fasting glucose reported as mg/dl
Insulinemia
insulin reported as µU/mL
Insulinemia
insulin reported as µU/mL
Secondary Outcome Measures
Full Information
NCT ID
NCT02951546
First Posted
October 26, 2016
Last Updated
May 26, 2022
Sponsor
University of Roma La Sapienza
Collaborators
Bambino Gesù Hospital and Research Institute, Università degli studi di Roma Foro Italico, Göteborg University
1. Study Identification
Unique Protocol Identification Number
NCT02951546
Brief Title
Metabolic Flexibility, Gut Microbiota, Healthy Diet and Exercise in NAFLD on Genetics Base
Official Title
Body Composition, Adiposity Phenotype, Metabolic Flexibility, and Gut Microbiota in PNPLA3 and TM6SF2 Gene Variant Carriers and Non-carriers With Nonalcoholic Fatty Liver Disease. Effects of a Nutritional Intervention Combined to Exercise
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
October 2016 (Actual)
Primary Completion Date
September 2021 (Actual)
Study Completion Date
February 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Roma La Sapienza
Collaborators
Bambino Gesù Hospital and Research Institute, Università degli studi di Roma Foro Italico, Göteborg University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Nonalcoholic fatty liver disease (NAFLD) is associated to obesity, metabolic syndrome and genetic predisposition: specific variants of the genes PNPLA3 and TM6SF2 are the most involved. Also biochemical mechanisms that affect the "metabolic flexibility" need to be better clarified.
It is known that a dietary intervention, accompanied by a physical personalized training, reduce either the hepatic fat content either insulin resistance.
Therefore, the aim of the study is to evaluate "metabolic flexibility" in obese NAFLD subjects taking in account the presence or absence of PNPLA3 and TM6SF2 polymorphism and the histopathological diagnosis of either simple steatosis or nonalcoholic steatohepatitis (NASH). The composition of gut microbiota will be also evaluated.
Finally, two distinct healthy dietary profiles accompanied by a personalized physical training, will be tested to comprehend whether and how "healthy diets" could operate in the clinical treatment of NAFLD and related conditions.
Detailed Description
Nonalcoholic fatty liver disease (NAFLD) is frequently associated to obesity and metabolic syndrome. In NAFLD, a heritable component to disease susceptibility has been demonstrated: the variants of the genes PNPLA3 and TM6SF2 are the most involved genetic determinants.
To date, biochemical mechanisms that affect the "metabolic flexibility" in obese NAFLD subjects, in presence or absence of genetic susceptibility, need to be better clarified.
Different studies demonstrated that a dietary intervention, accompanied by a physical personalized training, significantly reduce either the hepatic fat content either insulin resistance in overweight and obese subjects, independently of weight loss.
On these bases, the aim of the study is to evaluate "metabolic flexibility" in obese NAFLD subjects taking in account their genetics (presence or absence of PNPLA3 and TM6SF2 polymorphisms) and the histopathological diagnosis of either simple steatosis or nonalcoholic steatohepatitis (NASH). In addition, the composition of gut microbiota will be evaluated.
Finally, in this study, two distinct healthy dietary profiles accompanied by a personalized physical training, will be tested in order to comprehend whether and how "healthy diets" could be effective not only in the prevention, but also in the clinical treatment of NAFLD and other related conditions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-alcoholic Fatty Liver Disease, Obesity
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Nonalcoholic fatty liver disease (NAFLD) is associated to obesity, metabolic syndrome and genetic predisposition: specific variants of the genes PNPLA3 and TM6SF2 are the most involved. Also biochemical mechanisms that affect the "metabolic flexibility" need to be better clarified.
It is known that a dietary intervention and a physical personalized training, reduce either the hepatic fat content either insulin resistance.
Therefore, the aim of the study is to evaluate "metabolic flexibility" in obese NAFLD subjects taking in account the presence or absence of PNPLA3 and TM6SF2 polymorphism and the histopathological diagnosis of either simple steatosis or nonalcoholic steatohepatitis (NASH). The composition of gut microbiota will be also evaluated.
Finally, two distinct healthy dietary profiles accompanied by a personalized physical training, will be tested to comprehend whether and how "healthy diets" could operate in the clinical treatment of NAFLD and related conditions.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Mediterranean diet
Arm Type
Experimental
Arm Description
Hypocaloric Mediterranean diet for a 4-month period;
Aerobic exercise training for a 4-month period;
Arm Title
Low fat diet
Arm Type
Experimental
Arm Description
Hypocaloric low fat diet supplemented by branched and essential amino acids considering the total protein intake for a 4- month period;
Aerobic exercise training for a 4- month period;
Intervention Type
Dietary Supplement
Intervention Name(s)
Mediterranean diet
Intervention Description
In the Mediterranean diet fat intake will be equal to 35% of the total energy intake minus carbohydrate and protein energy carbohydrate as 65% of total calorie intake, dietary cholesterol <300 mg/day, dietary fiber 25 g/day.
Intervention Type
Dietary Supplement
Intervention Name(s)
Low fat diet
Intervention Description
In the hypocaloric low fat diet, fat will represent less than 25% of the total energy intake. Branched and essential amino acids will be administered taking into account the total protein intake.
Intervention Type
Other
Intervention Name(s)
Aerobic exercise
Intervention Description
A personalized program of aerobic exercise will be prescribed to the participants of both arms, following the "FITT" principles (frequency, intensity, time and type).
Primary Outcome Measure Information:
Title
Cholesterol assessment
Description
total cholesterol, HDL- cholesterol, LDL- cholesterol levels reported as mg/dl
Time Frame
baseline
Title
Cholesterol assessment
Description
total cholesterol, HDL- cholesterol, LDL- cholesterol levels reported as mg/dl
Time Frame
18 weeks after baseline
Title
triglycerides assessment
Description
tryglicerides levels reported as mg/dl
Time Frame
baseline
Title
triglycerides assessment
Description
tryglicerides levels reported as mg/dl
Time Frame
18 weeks after baseline
Title
metabolic flexibility variation in liver function;
Description
alanine aminotransferase (ALT) [U/L] , aspartate aminotransferase (AST) [UI/L]
Time Frame
baseline
Title
metabolic flexibility variation in liver function;
Description
alanine aminotransferase (ALT) [U/L] , aspartate aminotransferase (AST) [UI/L]
Time Frame
18 weeks after baseline
Title
Waist circumference measurements;
Description
waist circumference reported as cm
Time Frame
baseline
Title
Waist circumference measurements;
Description
waist circumference reported as cm
Time Frame
18 weeks after baseline
Title
anthropometric measurements;
Description
Body mass index reported as kg/m^2
Time Frame
baseline
Title
anthropometric measurements;
Description
Body mass index reported as kg/m^2
Time Frame
18 weeks after baseline
Title
Ultrasonographic examination;
Description
Liver ultrasonography according with criteria by Hamaguchi
Time Frame
baseline
Title
Ultrasonographic examination;
Description
Liver ultrasonography according with criteria by Hamaguchi
Time Frame
18 weeks after baseline
Title
Glucidic profile
Description
fasting glucose reported as mg/dl
Time Frame
baseline
Title
Glucidic profile
Description
fasting glucose reported as mg/dl
Time Frame
18 weeks after baseline
Title
Insulinemia
Description
insulin reported as µU/mL
Time Frame
baseline
Title
Insulinemia
Description
insulin reported as µU/mL
Time Frame
18 weeks after baseline
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
body mass index (BMI) > 30 Kg/m2 and < 40 Kg/m2;
Caucasian Italian subjects
hepatic steatosis according with ultrasonographic Hamaguchi's criteria and/or hypertransaminasemia (ALT >30 IU/L in men and >20 IU/L in women)
Exclusion Criteria:
any malignant disease during the last 5 years;
any inflammatory or autoimmune disease;
corticosteroids for systemic use;
renal failure (GFR<90 ml/min);
heart failure (NYHA classes II-IV);
history of viral or autoimmune liver disease;
any cause cirrhosis;
excessive alcohol intake (>140g/week for men and 70g/week for women);
participation in a reducing-weight program in the last 3 months;
level of physical activity higher than 3 METs;
therapy with antibiotics during the last 3 months;
bile salts, cholestyramine during the last 6 months before enrollment;
previous cholecystectomy;
gallbladder disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stefano Ginanni Corradini, MD, PhD
Organizational Affiliation
Department Translational and Precision Medicine, Sapienza University of Rome
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Translational and Precision Medicine, Sapienza University of Rome, Umberto I Hospital
City
Rome
ZIP/Postal Code
00185
Country
Italy
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Metabolic Flexibility, Gut Microbiota, Healthy Diet and Exercise in NAFLD on Genetics Base
We'll reach out to this number within 24 hrs